Engineered immune cells take aim at leukemia that evades standard therapy

NCT ID NCT04430530

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cells (CD22, CD123, CD38, CD10, and CD20). The study aims to see if this approach is safe and can shrink or eliminate the cancer. It enrolls children and adults over 6 months old from multiple medical centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 4SCAR-T cells targeting CD22, CD123, CD38, CD10, and CD20
What this could lead to: If successful, this approach could offer a new treatment option for patients with B-cell leukemia that no longer responds to standard anti-CD19 therapy.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply broadly. CAR-T therapy can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CD19 NEGATIVE B-CELL MALIGNANCIES

Contacts and locations

Locations

Shenzhen Geno-Immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.